Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06472362 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 11, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Jun 2024 to Nov 1, 2024
    • Primary completion date: Jun 2025 to Dec 2025
    • Site contacts updated at 7 of 7 sites
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.
Trial Details
NCT Number NCT06472362
Lead Sponsor Royal Brompton & Harefield NHS Foundation Trust
Collaborators: Imperial College London, Royal Free and University College Medical School, The Leeds Teaching Hospitals NHS Trust, Hannover Medical School, University of Siena, Università Politecnica delle Marche, Azienda Ospedaliero Universitaria di Sassari, Bichat Hospital
Conditions
(from sponsor)		 Systemic Sclerosis
Related terms Scleroderma, Systemic
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov